Millennium Management’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-983,809
| Closed | -$50.8M | – | 7725 |
|
|
2022
Q3 | $50.8M | Buy |
983,809
+613,117
| +165% | +$25.3M | 0.03% | 669 |
|
|
2022
Q2 | $9.19M | Sell |
370,692
-930,257
| -72% | -$20.5M | 0.01% | 2142 |
|
|
2022
Q1 | $32.6M | Buy |
1,300,949
+72,725
| +6% | +$2.04M | 0.02% | 959 |
|
|
2021
Q4 | $44.7M | Buy |
1,228,224
+946,776
| +336% | +$33.2M | 0.02% | 790 |
|
|
2021
Q3 | $4.81M | Buy |
281,448
+161,521
| +135% | +$2.52M | ﹤0.01% | 2901 |
|
|
2021
Q2 | $1.61M | Buy |
119,927
+75,413
| +169% | +$1.86M | ﹤0.01% | 4205 |
|
|
2021
Q1 | $2.28M | Buy |
+44,514
| New | +$2.68M | ﹤0.01% | 3416 |
|
|
2020
Q4 | – | Sell |
-93,056
| Closed | -$5.1K | – | 5734 |
|
|
2020
Q3 | $5.1K | Sell |
93,056
-128,776
| -58% | -$6.93M | 0.01% | 1825 |
|
|
2020
Q2 | $12.8M | Sell |
221,832
-133,399
| -38% | -$7.26M | 0.02% | 1047 |
|
|
2020
Q1 | $14.3M | Sell |
355,231
-19,753
| -5% | -$839K | 0.03% | 621 |
|
|
2019
Q4 | $14.8M | Sell |
374,984
-49,175
| -12% | -$863K | 0.02% | 1052 |
|
|
2019
Q3 | $2.88M | Buy |
+424,159
| New | +$3.18M | ﹤0.01% | 2207 |
|
|
2019
Q2 | – | Sell |
-49,812
| Closed | -$577K | – | 4633 |
|
|
2019
Q1 | $692K | Buy |
49,812
+32,999
| +196% | +$377K | ﹤0.01% | 3074 |
|
|
2018
Q4 | $183K | Sell |
16,813
-181,037
| -92% | -$1.91M | ﹤0.01% | 3418 |
|
|
2018
Q3 | $2.5M | Sell |
197,850
-190,025
| -49% | -$2.29M | ﹤0.01% | 2284 |
|
|
2018
Q2 | $5.11M | Buy |
387,875
+63,763
| +20% | +$763K | 0.01% | 1803 |
|
|
2018
Q1 | $4.41M | Buy |
324,112
+68,281
| +27% | +$704K | 0.01% | 1889 |
|
|
2017
Q4 | $1.52M | Buy |
255,831
+37,069
| +17% | +$254K | ﹤0.01% | 2443 |
|
|
2017
Q3 | $1.62M | Buy |
218,762
+97,883
| +81% | +$814K | ﹤0.01% | 2272 |
|
|
2017
Q2 | $1.13M | Sell |
120,879
-32,369
| -21% | -$238K | ﹤0.01% | 2384 |
|
|
2017
Q1 | $1.12M | Buy |
153,248
+107,890
| +238% | +$777K | ﹤0.01% | 2336 |
|
|
2016
Q4 | $336K | Buy |
45,358
+29,703
| +190% | +$214K | ﹤0.01% | 2844 |
|
|
2016
Q3 | $95K | Buy |
15,655
+2,483
| +19% | +$11.7K | ﹤0.01% | 3143 |
|
|
2016
Q2 | $59K | Buy |
+13,172
| New | +$49.4K | ﹤0.01% | 3062 |
|
|
2015
Q4 | – | Sell |
-60,718
| Closed | -$367K | – | 3875 |
|
|
2015
Q3 | $367K | Sell |
60,718
-11,428
| -16% | -$82.6K | ﹤0.01% | 2814 |
|
|
2015
Q2 | $594K | Sell |
72,146
-51,507
| -42% | -$409K | ﹤0.01% | 2545 |
|
|
2015
Q1 | $934K | Sell |
123,653
-271,347
| -69% | -$2.12M | ﹤0.01% | 2353 |
|
|
2014
Q4 | $2.7M | Buy |
395,000
+368,597
| +1,396% | +$1.95M | 0.01% | 1777 |
|
|
2014
Q3 | $119K | Buy |
+26,403
| New | +$140K | ﹤0.01% | 3519 |
|
|
2014
Q2 | – | Sell |
-61,111
| Closed | -$405K | – | 4021 |
|
|
2014
Q1 | $405K | Buy |
61,111
+45,011
| +280% | +$313K | ﹤0.01% | 2758 |
|
|
2013
Q4 | $93K | Sell |
16,100
-151,203
| -90% | -$780K | ﹤0.01% | 3346 |
|
|
2013
Q3 | $930K | Sell |
167,303
-120,418
| -42% | -$1.3M | ﹤0.01% | 2157 |
|
|
2013
Q2 | $4.07M | Buy |
+287,721
| New | +$3.73M | 0.01% | 1149 |
|
Other funds holding CCXI
Millennium Management's CCXI Position: Q4 2022 in Review
Millennium Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 983,809 shares — an estimated $50.8M sold.
Millennium Management first reported a position in CCXI in Q2 2013 and held it in 33 quarters. The position peaked at $50.8M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Millennium Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Millennium Management sold 983,809 ChemoCentryx, Inc. shares in Q4 2022, an estimated $50.8M.
- Millennium Management first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 33 quarters.
- Millennium Management's ChemoCentryx, Inc. position peaked at $50.8M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.